Skip to content
Skip to main content
Toggle
Toggle
Search
Submit
X
People
Insights
Expand Children
Agenda
Reports
Courses
Events
Expertise
Expand Children
Analytics and Data Science
Antitrust
Antitrust Damages
Behavioural Economics
Collective and Class Actions
Commercial Litigation and International Arbitration
Finance and Valuation
Governance
Infrastructure
Intellectual Property
Market Investigations
Mergers
Performance, Productivity and Efficiency
Public Policy and Impact Assessment
Regulation
State Aid and Subsidy Control
Strategy
Sustainability and Climate Change
Transaction Advice
Sectors
Expand Children
Digital
Energy
Financial Services
Pharmaceuticals and Life Sciences
Retail and Consumer
Postal and Logistics
Telecoms, Media and Technology
Transport
Water
Careers
Expand Children
Current vacancies
Early Careers
Locations
Expand Children
Belgium
France
Germany
Italy
Netherlands
United Kingdom
About us
Expand Children
Celebrating 40 years
Climate Commitment
Diversity and Inclusion
Media Centre
Oxera Economics Council
Home
/
Insights
/
Agenda
Shades of grey: arguments for and against parallel trade in pharmaceuticals
14 October
2008
Download
Share
Back to top
What's on
your mind?
Get in touch to talk to our team
